Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | KDM6B | O15054 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659061 | 0.88 | HCAR2 (0.42) | HCAR2POLBTSHRKDM4EALDH1A1 | |
| SCHEMBL29157397 | 0.84 | HCAR2 (0.39) | HCAR2POLBTSHRKDM4EALDH1A1 | |
| SCHEMBL12164567 | 0.84 | HCAR2 (0.39) | HCAR2POLBTSHRKDM4EALDH1A1 | |
| SCHEMBL28723383 | 0.78 | KDM4E (0.43) | HCAR2POLBKDM4EALDH1A1MEN1 | |
| SCHEMBL21749937 | 0.77 | HCAR2 (0.41) | HCAR2POLBTSHRKDM4EALDH1A1 | |
| SCHEMBL15334246 | 0.77 | AKR1C3 (0.50) | HCAR2POLBTSHRKDM4EALDH1A1 | |
| SCHEMBL20512962 | 0.76 | SELL (0.42) | HCAR2POLBKDM4EALDH1A1MEN1 | |
| SCHEMBL1171212 | 0.76 | KDM4E (0.47) | HCAR2POLBKDM4EALDH1A1MEN1 | |
| SCHEMBL465860 | 0.75 | KDM4E (0.42) | HCAR2POLBKDM4EALDH1A1MEN1 | |
| SCHEMBL16694995 | 0.75 | HCAR2 (0.39) | HCAR2POLBTSHRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291523-B2 | LXR modulators with bicyclic core moiety | ORSOBIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240317726-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO, INC. | 2024-09-26 | — | — | US | disclosed |
| US-11970484-B2 | LXR modulators with bicyclic core moiety | ORSOBIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| EP-3814331-B9 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3814331-B1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-06-14 | — | — | EP | disclosed |
| US-11618747-B2 | LXR modulators with bicyclic core moiety | ORSOBIO, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX-FXR GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX-FXR GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| EP-3814331-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | Phenex-FXR GmbH (DE) | 2021-05-05 | — | — | EP | disclosed |
| CN-112689630-A | Novel LXR modulators with bicyclic core moieties | 菲尼克斯-FXR股份有限公司 | 2021-04-20 | — | — | CN | disclosed |
| US-20190296246-A1 | ORGANIC EL MATERIAL AND ORGANIC EL ELEMENT EMPLOYING SAME | KANEKA CORPORATION (JP) | 2019-09-26 | — | — | US | disclosed |
| EP-3316328-A1 | ORGANIC EL MATERIAL AND ORGANIC EL ELEMENT EMPLOYING SAME | Kaneka Corporation (JP) | 2018-05-02 | — | — | EP | disclosed |
| EP-3316328-A1 | ORGANIC EL MATERIAL AND ORGANIC EL ELEMENT EMPLOYING SAME | Kaneka Corporation (JP) | 2018-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317726-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NCOA3 | HCAR2 160/4885POLB 4749/4885TSHR 413/4885 |
| US-11618747-B2 | LXR modulators with bicyclic core moiety | NR1H2, NR1H3, NR1H4 | HCAR2 149/4885POLB 4556/4885TSHR 364/4885 |
| US-20190296246-A1 | ORGANIC EL MATERIAL AND ORGANIC EL ELEMENT EMPLOYING SAME | ELP1, ELF3, ELOB | HCAR2 4436/4885POLB 2155/4885TSHR 4410/4885 |
| US-12291523-B2 | LXR modulators with bicyclic core moiety | NR1H2, NR1H3, NR1H4 | HCAR2 157/4885POLB 4720/4885TSHR 362/4885 |
| US-11970484-B2 | LXR modulators with bicyclic core moiety | NR1H2, NR1H3, NR1H4 | HCAR2 149/4885POLB 4556/4885TSHR 364/4885 |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | HCAR2 155/4885POLB 4648/4885TSHR 424/4885 |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | HCAR2 155/4885POLB 4648/4885TSHR 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.